SCHEMBL140355

SCHEMBL140355

CNC(=O)OCC(O)CO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.46
KDM4E B2RXH2 1/20 0.46
DUSP3 P51452 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CHRNB2 P17787 2/20 0.41
CHRNA4 P43681 2/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41
CYP2D6 P10635 1/20 0.41
CHRM1 P11229 1/20 0.41
NFKB1 P19838 1/20 0.41
CHRM3 P20309 1/20 0.41
MAPK1 P28482 1/20 0.41
CHRNA7 P36544 1/20 0.41
APEX1 P27695 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
EPHX1 P07099 1/20 0.39
DGKA P23743 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27558053 1.00 LMNA (0.46) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL21344297 1.00 LMNA (0.46) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL13347915 0.89 CHRNB2 (0.45) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL10068167 0.83 CYP1A2 (0.44) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL21098353 0.81 CHRNB2 (0.44) LMNAKDM4ECHRNB2CHRNA4CHRM2
SCHEMBL19853430 0.81 CHRNB2 (0.44) LMNAMEN1KMT2ACHRNB2CHRNA4
SCHEMBL6841404 0.80 LMNA (0.43) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL28474276 0.80 CHRNB2 (0.42) LMNAKDM4ECHRNB2CHRNA4CHRM2
SCHEMBL9681883 0.79 SMN1; SMN2 (0.49) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL19651542 0.79 LMNA (0.43) LMNAKDM4EDUSP3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3855241-B1 CONTACT LENS TREATMENT SOLUTION NOF CORP (JP) 2024-01-24 EP disclosed
EP-3855241-A1 CONTACT LENS TREATMENT SOLUTION NOF Corporation (JP) 2021-07-28 EP disclosed
WO-2020059593-A1 CONTACT LENS TREATMENT SOLUTION 日油株式会社 2020-03-26 WO disclosed
US-20170342046-A1 Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders CATABASIS PHARMACEUTICALS, INC. 2017-11-30 US disclosed
US-9777245-B2 Methods of fractionating metathesized triacylglycerol polyols and uses thereof TRENT UNIVERSITY (CA) 2017-10-03 US disclosed
US-9408919-B2 Biodegradable polymer—bioactive moiety conjugates POLYACTIVA PTY LTD. (AU) 2016-08-09 US disclosed
US-8652568-B2 Coating composition DOW GLOBAL TECHNOLOGIES LLC (US) 2014-02-18 US disclosed
US-8652568-B2 Coating composition DOW GLOBAL TECHNOLOGIES LLC (US) 2014-02-18 US disclosed
US-20140046018-A1 BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES POLYACTIVA PTY LTD. (AU) 2014-02-13 US disclosed
US-8535655-B2 Biodegradable polymer—bioactive moiety conjugates POLYACTIVA PTY LTD. (AU) 2013-09-17 US disclosed
US-20120059107-A1 COATING COMPOSITION DOW GLOBAL TECHNOLOGIES LLC 2012-03-08 US disclosed
US-20120059107-A1 COATING COMPOSITION DOW GLOBAL TECHNOLOGIES LLC 2012-03-08 US disclosed
EP-2426158-A1 A coating composition Dow Global Technologies LLC (US) 2012-03-07 EP disclosed
US-20110243884-A1 BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES THE BIONICS INSTITUTE OF AUSTRALIA (AU) 2011-10-06 US disclosed
EP-1513527-A1 PRODRUGS OF IMIDAZOLE DERIVATIVES, FOR USE AS PROTON PUMP INHIBITORS IN THE TREATMENT OF E.G. PEPTIC ULCERS Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003105845-A1 PRODRUGS OF IMIDAZOLE DERIVATIVES, FOR USE AS PROTON PUMP INHIBITORS IN THE TREATMENT OF E.G. PEPTIC ULCERS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342046-A1 Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders CPT2, FABP1, ACAA2 LMNA 3607/4885KDM4E 4176/4885DUSP3 2700/4885
US-20140046018-A1 BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES BMP2, MKI67, FGF2 LMNA 2564/4885KDM4E 2847/4885DUSP3 1804/4885
US-20110243884-A1 BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES BMP2, MKI67, FGF2 LMNA 2564/4885KDM4E 2847/4885DUSP3 1804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.